U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C21H25ClN2O3.2ClH
Molecular Weight 461.8103
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CETIRIZINE HYDROCHLORIDE

SMILES

c1ccc(cc1)C(c2ccc(cc2)Cl)N3CCN(CC3)CCOCC(=O)O.Cl.Cl

InChI

InChIKey=PGLIUCLTXOYQMV-UHFFFAOYSA-N
InChI=1S/C21H25ClN2O3.2ClH/c22-19-8-6-18(7-9-19)21(17-4-2-1-3-5-17)24-12-10-23(11-13-24)14-15-27-16-20(25)26;;/h1-9,21H,10-16H2,(H,25,26);2*1H

HIDE SMILES / InChI

Molecular Formula C21H25ClN2O3
Molecular Weight 388.8885
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Molecular Formula ClH
Molecular Weight 36.4609
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment:: https://www.drugs.com/pro/cetirizine.html

Cetirizine, a human metabolite of hydroxyzine, is an antihistamine; its principal effects are mediated via selective inhibition of peripheral H1 receptors. It is indicated for the relief of nasal and non-nasal symptoms associated with seasonal or perennial allergic rhinitis, hay fever and chronic idiopathic urticaria. Commonly reported adverse reactions of cetirizine include headache, dry mouth and drowsiness or fatigue. Pharmacokinetic interaction studies with Cetirizine in adults were conducted with pseudoephedrine, antipyrine, ketoconazole, erythromycin and azithromycin. No interactions were observed.

CNS Activity

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
ZYRTEC HIVES RELIEF

Approved Use

Tablets should be administered when both the antihistaminic properties of cetirizine hydrochloride and the nasal decongestant properties of pseudoephedrine hydrochloride are desired.

Launch Date

818380800000
Palliative
ZYRTEC HIVES RELIEF

Approved Use

Tablets should be administered when both the antihistaminic properties of cetirizine hydrochloride and the nasal decongestant properties of pseudoephedrine hydrochloride are desired.

Launch Date

818380800000
Palliative
ZYRTEC HIVES RELIEF

Approved Use

Uses temporarily relieves these symptoms due to hay fever or other upper respiratory allergies: •runny nose •sneezing •itchy, watery eyes •itching of the nose or throat

Launch Date

818380800000
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
311 ng/mL
10 mg 1 times / day multiple, oral
dose: 10 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
CETIRIZINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
978.4 ng/mL
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CETIRIZINE plasma
Homo sapiens
population: UNHEALTHY
age: CHILD
sex: FEMALE / MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
6375.6 ng × h/mL
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CETIRIZINE plasma
Homo sapiens
population: UNHEALTHY
age: CHILD
sex: FEMALE / MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
8.3 h
10 mg 1 times / day multiple, oral
dose: 10 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
CETIRIZINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
6.9 h
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CETIRIZINE plasma
Homo sapiens
population: UNHEALTHY
age: CHILD
sex: FEMALE / MALE
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
7%
10 mg 1 times / day multiple, oral
dose: 10 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
CETIRIZINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
180 mg single, oral
Overdose
Dose: 180 mg
Route: oral
Route: single
Dose: 180 mg
Sources:
unhealthy, 18 months
Health Status: unhealthy
Age Group: 18 months
Sex: M
Sources:
270 mg single, oral
Overdose
Dose: 270 mg
Route: oral
Route: single
Dose: 270 mg
Sources:
unhealthy, 18 years
Health Status: unhealthy
Age Group: 18 years
Sex: F
Sources:
Other AEs: Metabolic acidosis, Hypokalemia...
Other AEs:
Metabolic acidosis (grade 5, 1 patient)
Hypokalemia (grade 5, 1 patient)
Sources:
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
unhealthy, 18 years
Health Status: unhealthy
Age Group: 18 years
Sex: F
Sources:
Disc. AE: Delusions, Depression...
AEs leading to
discontinuation/dose reduction:
Delusions (1 patient)
Depression (1 patient)
Sources:
2.5 mg 1 times / day multiple, oral
Dose: 2.5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 2.5 mg, 1 times / day
Sources:
unhealthy, 23 months
Health Status: unhealthy
Age Group: 23 months
Sex: M
Sources:
Disc. AE: Insomnia...
AEs leading to
discontinuation/dose reduction:
Insomnia (1 patient)
Sources:
10 mg single, intravenous
Recommended
unhealthy, 39 years
Other AEs: Dyspepsia, Feeling hot...
Other AEs:
Dyspepsia (1%)
Feeling hot (1%)
Dysgeusia (1%)
Headache (1%)
Paresthesia (1%)
Presyncope (1%)
Hyperhidrosis (1%)
Sources:
60 mg single, oral
Overdose
Dose: 60 mg
Route: oral
Route: single
Dose: 60 mg
Sources:
healthy, 4 years
Health Status: healthy
Age Group: 4 years
Sex: M
Sources:
Other AEs: Drowsiness, Sedation...
Other AEs:
Drowsiness (severe, 1 patient)
Sedation (1 patient)
Sources:
50 mg 1 times / day multiple, oral
Dose: 50 mg, 1 times / day
Route: oral
Route: multiple
Dose: 50 mg, 1 times / day
Sources:
unhealthy, 46 years
Health Status: unhealthy
Age Group: 46 years
Sex: M
Sources:
5 mg 1 times / day multiple, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg, 1 times / day
Sources:
unhealthy, 6 years
Health Status: unhealthy
Age Group: 6 years
Sex: M
Sources:
Disc. AE: Dystonic reaction...
AEs leading to
discontinuation/dose reduction:
Dystonic reaction (1 patient)
Sources:
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
unhealthy, > 12 years
Health Status: unhealthy
Age Group: > 12 years
Sex: M+F
Sources:
Other AEs: Somnolence, Fatigue...
Other AEs:
Somnolence (13.7%)
Fatigue (5.9%)
Dry mouth (5%)
Dizziness (2%)
Pharyngitis (2%)
Sources:
0.24 % 2 times / day multiple, ophthalmic
Recommended
unhealthy, adult
Other AEs: Ocular hyperemia, Visual acuity reduced...
AEs

AEs

AESignificanceDosePopulation
Hypokalemia grade 5, 1 patient
270 mg single, oral
Overdose
Dose: 270 mg
Route: oral
Route: single
Dose: 270 mg
Sources:
unhealthy, 18 years
Health Status: unhealthy
Age Group: 18 years
Sex: F
Sources:
Metabolic acidosis grade 5, 1 patient
270 mg single, oral
Overdose
Dose: 270 mg
Route: oral
Route: single
Dose: 270 mg
Sources:
unhealthy, 18 years
Health Status: unhealthy
Age Group: 18 years
Sex: F
Sources:
Delusions 1 patient
Disc. AE
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
unhealthy, 18 years
Health Status: unhealthy
Age Group: 18 years
Sex: F
Sources:
Depression 1 patient
Disc. AE
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
unhealthy, 18 years
Health Status: unhealthy
Age Group: 18 years
Sex: F
Sources:
Insomnia 1 patient
Disc. AE
2.5 mg 1 times / day multiple, oral
Dose: 2.5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 2.5 mg, 1 times / day
Sources:
unhealthy, 23 months
Health Status: unhealthy
Age Group: 23 months
Sex: M
Sources:
Dysgeusia 1%
10 mg single, intravenous
Recommended
unhealthy, 39 years
Dyspepsia 1%
10 mg single, intravenous
Recommended
unhealthy, 39 years
Feeling hot 1%
10 mg single, intravenous
Recommended
unhealthy, 39 years
Headache 1%
10 mg single, intravenous
Recommended
unhealthy, 39 years
Hyperhidrosis 1%
10 mg single, intravenous
Recommended
unhealthy, 39 years
Paresthesia 1%
10 mg single, intravenous
Recommended
unhealthy, 39 years
Presyncope 1%
10 mg single, intravenous
Recommended
unhealthy, 39 years
Sedation 1 patient
60 mg single, oral
Overdose
Dose: 60 mg
Route: oral
Route: single
Dose: 60 mg
Sources:
healthy, 4 years
Health Status: healthy
Age Group: 4 years
Sex: M
Sources:
Drowsiness severe, 1 patient
60 mg single, oral
Overdose
Dose: 60 mg
Route: oral
Route: single
Dose: 60 mg
Sources:
healthy, 4 years
Health Status: healthy
Age Group: 4 years
Sex: M
Sources:
Dystonic reaction 1 patient
Disc. AE
5 mg 1 times / day multiple, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg, 1 times / day
Sources:
unhealthy, 6 years
Health Status: unhealthy
Age Group: 6 years
Sex: M
Sources:
Somnolence 13.7%
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
unhealthy, > 12 years
Health Status: unhealthy
Age Group: > 12 years
Sex: M+F
Sources:
Dizziness 2%
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
unhealthy, > 12 years
Health Status: unhealthy
Age Group: > 12 years
Sex: M+F
Sources:
Pharyngitis 2%
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
unhealthy, > 12 years
Health Status: unhealthy
Age Group: > 12 years
Sex: M+F
Sources:
Dry mouth 5%
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
unhealthy, > 12 years
Health Status: unhealthy
Age Group: > 12 years
Sex: M+F
Sources:
Fatigue 5.9%
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
unhealthy, > 12 years
Health Status: unhealthy
Age Group: > 12 years
Sex: M+F
Sources:
Visual acuity reduced 0.6%
0.24 % 2 times / day multiple, ophthalmic
Recommended
unhealthy, adult
Ocular hyperemia 2%
0.24 % 2 times / day multiple, ophthalmic
Recommended
unhealthy, adult
Conjunctival hyperemia 5.3%
0.24 % 2 times / day multiple, ophthalmic
Recommended
unhealthy, adult
PubMed

PubMed

TitleDatePubMed
Efficacy and safety of levocetirizine in seasonal allergic rhinitis.
2001
Cetirizine/pseudoephedrine.
2001
Clinical prescribing of allergic rhinitis medication in the preschool and young school-age child: what are the options?
2001
Design, synthesis and antihistaminic (H1)activity of some condensed 2-(substituted)arylaminoethylpyrimidin-4(3H)-ones.
2001
Safety of antihistamines in children.
2001
Prevention of acute urticaria in young children with atopic dermatitis.
2001 Apr
Effect of cetirizine, levocetirizine, and dextrocetirizine on histamine-induced nasal response in healthy adult volunteers.
2001 Apr
Newer antihistamines.
2001 Apr 30
Absorption and disposition of levocetirizine, the eutomer of cetirizine, administered alone or as cetirizine to healthy volunteers.
2001 Aug
Sure outcomes of random events: a model for clinical trials.
2001 Feb 28
[Prednicarbate and cetirizin dihydrochloride in the treatment of atopic eczema in the acute phase in children].
2001 Jan
Effects of monotherapy with intra-nasal corticosteroid or combined oral histamine and leukotriene receptor antagonists in seasonal allergic rhinitis.
2001 Jan
Urticaria induced by cetirizine.
2001 Jan
Effect of cetirizine on bronchial hyperresponsiveness in patients with seasonal allergic rhinitis and asthma.
2001 Jan
Stability of cetirizine dihydrochloride in solid state.
2001 Jan-Feb
Double-blind multicenter study on the efficacy and tolerability of cetirizine compared with oxatomide in chronic idiopathic urticaria in preschool children.
2001 Jul
Stability indicating HPTLC method for the simultaneous determination of pseudoephedrine and cetirizine in pharmaceutical formulations.
2001 Jun
[Co-administration of histamine H1 antagonist and oral anticoagulants].
2001 Jun-Jul
An investigation into the effects of cetirizine on cognitive function and psychomotor performance in healthy volunteers.
2001 Mar
Do antihistamines have a role in asthma therapy?
2001 Mar
[The course of allergy: principles for early diagnosis, prevention and early therapy of allergic diseases].
2001 May
Inhibition of depolarization-induced [3H]noradrenaline release from SH-SY5Y human neuroblastoma cells by some second-generation H(1) receptor antagonists through blockade of store-operated Ca(2+) channels (SOCs).
2001 Nov 1
[Efficacy and safety of fexofenadine and cetirizine in the treatment of allergic rhinitis].
2001 Nov-Dec
Preclinical comparison of ebastine and other second generation H1-antihistamines.
2001 Oct
Absorption, distribution, metabolism and excretion of [14C]levocetirizine, the R enantiomer of cetirizine, in healthy volunteers.
2001 Oct
Effects of topical corticosteroid and combined mediator blockade on domiciliary and laboratory measurements of nasal function in seasonal allergic rhinitis.
2001 Oct
The costs of nonsedating antihistamine therapy for allergic rhinitis in managed care: an updated analysis.
2001 Oct
Cetirizine inhibits skin reactions but not mediator release in immediate and developing late-phase allergic cutaneous reactions. A double-blind, placebo-controlled study.
2001 Sep
Photosensitivity disorders: cause, effect and management.
2002
[Comparative antihistamine and anti-allergic effects of various antihistamine preparations].
2002
Displacement of histamine from liver cells and cell components by ligands for cytochromes P450.
2002
[The first case of lasting pigmented toxidermia induced by cetirizine (Zyrtec, Virlix) and ticlopidine].
2002 Apr
Major role for the carboxylic function of cetirizine and levocetirizine in their binding characteristics to human H1-histamine-receptors.
2002 Apr
Randomised controlled trial of butterbur and cetirizine for treating seasonal allergic rhinitis.
2002 Jan 19
Gateways to clinical trials.
2002 Jan-Feb
Cetirizine decreases interleukin-4, interleukin-5, and interferon-gamma gene expressions in nasal-associated lymphoid tissue of sensitized mice.
2002 Jan-Feb
Immune changes in patients with advanced breast cancer undergoing chemotherapy with taxanes.
2002 Jul 1
Comparison of cetirizine, ebastine and loratadine in the treatment of immediate mosquito-bite allergy.
2002 Jun
[Skin prick test results in snoring and sleep apnea patients].
2002 Mar
Comparative activity of cetirizine and mizolastine on histamine-induced skin wheal and flare responses at 24 h.
2002 Mar
[Already allergic to pollen in early childhood. Can future asthma still be prevented?].
2002 Mar 7
Gateways to clinical trials.
2002 May
Patents

Sample Use Guides

1 to 2 tablets once daily depending upon severity of symptoms; do not take more than 2 tablets in 24 hours
Route of Administration: Oral
In Vitro Use Guide
Cetirizine (10 micrograms/ml) significantly enhanced IL-1 release by human monocytes stimulated by a weak LPS concentration (1 microgram/ml) but could not modify the maximal increase of IL-1 release induced by 10 micrograms/ml of LPS. It did not exert any effect on resting cells. Cetirizine (0.1-10 micrograms/ml) enhanced PGE2 release by resting human monocytes. Concentrations of 1 and 10 micrograms/ml enhanced PGE2 release by LPS-stimulated monocytes, and by healthy and inflamed rat macrophages.
Substance Class Chemical
Created
by admin
on Fri Jun 25 21:01:46 UTC 2021
Edited
by admin
on Fri Jun 25 21:01:46 UTC 2021
Record UNII
64O047KTOA
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CETIRIZINE HYDROCHLORIDE
JAN   MART.   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD  
USAN  
Official Name English
CETIRIZINE HYDROCHLORIDE [USP MONOGRAPH]
Common Name English
CETIRIZINE HYDROCHLORIDE [VANDF]
Common Name English
CETIRIZINE HCL
Common Name English
ACETIC ACID, (2-(4-((4-CHLOROPHENYL)PHENYLMETHYL)-1-PIPERAZINYL)ETHOXY)-, DIHYDROCHLORIDE, (+/-)-
Common Name English
QUZYTTIR
Brand Name English
CETIRIZINE DIHYDROCHLORIDE [EP MONOGRAPH]
Common Name English
CETIRIZINE HYDROCHLORIDE [USP-RS]
Common Name English
NSC-759102
Code English
(+/-)-(2-(4-(P-CHLORO-A-PHENYLBENZYL)-1-PIPERAZINYL)ETHOXY)ACETIC ACID, DIHYDROCHLORIDE
Common Name English
ZYRTEC
Brand Name English
CETIRIZINE HYDROCHLORIDE [WHO-DD]
Common Name English
CETIRIZINE HYDROCHLORIDE [ORANGE BOOK]
Common Name English
CETIRIZINE DIHYDROCHLORIDE [MI]
Common Name English
CETRINE
Brand Name English
CETIRIZINE HYDROCHLORIDE [MART.]
Common Name English
CETIRIZINE HYDROCHLORIDE [JAN]
Common Name English
P-071
Code English
2-(2-(4-(P-CHLORO-ALPHA-PHENYLBENZYL)1-PIPERAZINYL)ETHOXY) ACETIC ACID DIHYDROCHLORIDE
Systematic Name English
CETIRIZINE HYDROCHLORIDE [USAN]
Common Name English
CETIRIZINE HYDROCHLORIDE COMPONENT OF ZYRTEC-D
Common Name English
ZERVIATE
Brand Name English
CETIRIZINE DIHYDROCHLORIDE
EP   MI  
Common Name English
P 071
Code English
ZYRTEC-D COMPONENT CETIRIZINE HYDROCHLORIDE
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C29578
Created by admin on Fri Jun 25 21:01:46 UTC 2021 , Edited by admin on Fri Jun 25 21:01:46 UTC 2021
Code System Code Type Description
USP_CATALOG
1102929
Created by admin on Fri Jun 25 21:01:46 UTC 2021 , Edited by admin on Fri Jun 25 21:01:46 UTC 2021
PRIMARY USP-RS
RXCUI
203150
Created by admin on Fri Jun 25 21:01:46 UTC 2021 , Edited by admin on Fri Jun 25 21:01:46 UTC 2021
PRIMARY RxNorm
EVMPD
SUB11803MIG
Created by admin on Fri Jun 25 21:01:46 UTC 2021 , Edited by admin on Fri Jun 25 21:01:46 UTC 2021
PRIMARY
EPA CompTox
83881-52-1
Created by admin on Fri Jun 25 21:01:46 UTC 2021 , Edited by admin on Fri Jun 25 21:01:46 UTC 2021
PRIMARY
MERCK INDEX
M3291
Created by admin on Fri Jun 25 21:01:46 UTC 2021 , Edited by admin on Fri Jun 25 21:01:46 UTC 2021
PRIMARY Merck Index
CAS
83881-52-1
Created by admin on Fri Jun 25 21:01:46 UTC 2021 , Edited by admin on Fri Jun 25 21:01:46 UTC 2021
PRIMARY
NCI_THESAURUS
C28920
Created by admin on Fri Jun 25 21:01:46 UTC 2021 , Edited by admin on Fri Jun 25 21:01:46 UTC 2021
PRIMARY
PUBCHEM
55182
Created by admin on Fri Jun 25 21:01:46 UTC 2021 , Edited by admin on Fri Jun 25 21:01:46 UTC 2021
PRIMARY
FDA UNII
64O047KTOA
Created by admin on Fri Jun 25 21:01:46 UTC 2021 , Edited by admin on Fri Jun 25 21:01:46 UTC 2021
PRIMARY
DRUG BANK
DBSALT001214
Created by admin on Fri Jun 25 21:01:46 UTC 2021 , Edited by admin on Fri Jun 25 21:01:46 UTC 2021
PRIMARY
ChEMBL
CHEMBL1000
Created by admin on Fri Jun 25 21:01:46 UTC 2021 , Edited by admin on Fri Jun 25 21:01:46 UTC 2021
PRIMARY
Related Record Type Details
TRANSPORTER -> INHIBITOR
PARENT -> SALT/SOLVATE
BASIS OF STRENGTH->SUBSTANCE
ASSAY (HPLC)
USP
Related Record Type Details
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
For the calculation of content, multiply the peak areas by 0.7
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
For the calculation of content, multiply the peak areas by 0.6
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
For the calculation of content, multiply the peak areas by 1.9
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
For the calculation of content, multiply the peak areas by 1.3
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Related Record Type Details
ACTIVE MOIETY